Key Points
- Director Bruce Booth sold 229,809 Kymera shares on Dec. 10 at an average price of $91.73 for about $21.08 million, trimming his stake by 25.08% to 686,477 shares (≈$62.97M).
- Wall Street is largely bullish: the stock has a consensus "Buy" rating with an average price target of $112.80 and several firms raising targets into the $112–$116 range.
- Kymera recently missed quarterly expectations—EPS of -$0.90 vs. -$0.71 est. and revenue $2.76M vs. $23.15M est.—and reported very negative margins and return on equity.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 678 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12. Following the transaction, the director owned 685,393 shares of the company's stock, valued at $62,398,178.72. The trade was a 0.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Bruce Booth also recently made the following trade(s):
- On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.23, for a total transaction of $556,594.23.
- On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.73, for a total transaction of $21,080,379.57.
Kymera Therapeutics Price Performance
Shares of NASDAQ KYMR opened at $89.68 on Friday. The business has a 50-day moving average of $64.77 and a 200-day moving average of $51.85. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.19). The company had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have commented on KYMR. Morgan Stanley increased their price target on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an "overweight" rating in a research note on Tuesday. BTIG Research set a $138.00 target price on shares of Kymera Therapeutics in a report on Monday. Oppenheimer lifted their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an "outperform" rating in a report on Tuesday. Bank of America boosted their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Citigroup raised their price objective on Kymera Therapeutics from $80.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of "Buy" and an average target price of $112.80.
Get Our Latest Analysis on Kymera Therapeutics
Institutional Investors Weigh In On Kymera Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its position in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after purchasing an additional 540 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after purchasing an additional 770 shares during the period. Bessemer Group Inc. grew its holdings in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after buying an additional 815 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after buying an additional 1,083 shares during the period.
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
